-
-
-
-
-
-
News
-
-
Contact UsThe company focuses on the research, development, production, and sales of chemical raw materials and their formulations. All products have passed national GMP certification, and core products have successively passed official pharmaceutical regulatory certifications from multiple countries, including the EU EDQM, US FDA, Japanese PMDA, and South Korean MFDS. Following its successful listing on the Shenzhen Stock Exchange's ChiNext board on April 4, 2023, Keyuan Pharmaceutical has entered a phase of rapid development driven by both digital intelligence and capital, with its business spanning dozens of countries and regions worldwide.
Surging momentum, a powerful display! Keyuan Pharmaceutical’s wholly owned subsidiary made a major appearance at the 93rd China International Pharmaceutical Fair!
Publish Time:
2026-10-27
In the golden autumn of October, Beijing gathers momentum. On October 21, the 93rd National Pharmaceutical Fair, themed “Open China, Healthy World,” grandly opened at the China International Exhibition Center in Shunyi, Beijing.
In the golden autumn of October, Beijing gathers momentum. On October 21, the 93rd National Pharmaceutical Fair, themed “Open China, Healthy World,” grandly opened at the China International Exhibition Center in Shunyi, Beijing. As an innovative, publicly listed company in China’s chemical pharmaceutical sector, Keyuan Pharmaceutical (stock code: 301281.SZ) showcased its full‑scale presence through its wholly owned subsidiary, Shandong Linuo Pharmaceutical Co., Ltd. The company unveiled a diverse portfolio of dosage forms and several high‑impact new products, highlighting its robust capabilities. Chairman Li Hongfu led the marketing team in in-depth discussions with both longstanding and new clients, sending a clear signal to the industry of open collaboration and accelerated growth.
A diverse array of dosage forms converges, with blockbuster new products stealing the spotlight.
Leveraging the synergistic advantages of its parent company’s “integrated API–formulation” and “excipient–formulation” models, Linuo Pharmaceutical showcased on-site a comprehensive product portfolio spanning multiple dosage forms—including solid dosage forms, injectables, oral solutions, capsules, drops, liniments, pastes, and sprays—and highlighted several high‑impact new products. The company’s strategic, in‑depth expansion across key therapeutic areas—cardiovascular, antidiabetic, psychoneurological, anti‑inflammatory and antibacterial, and respiratory—was on full display, with a rapidly evolving product roadmap that covers major clinical settings, drawing significant attention from industry peers and partners.
An open posture is deepening exchanges, and the momentum of development is steadily improving.
During the exhibition, the company engaged in numerous in-depth discussions with both new and existing customers, adopting an open‑minded approach. Focusing on areas such as product empowerment, joint channel development, and market expansion, they jointly explored new avenues for collaboration and mapped out a fresh roadmap for growth, with several promising cooperation initiatives rapidly moving toward implementation.
Behind the surge in collaborative momentum lies the robust foundation underpinning the company’s high‑quality growth: in the first half of 2026, its operating revenue increased by 45.47% year over year, and net profit rose by 51.56%, marking a new pace of expansion. Anchored by a product portfolio that addresses core, enduring demand, bolstered by pioneering smart‑manufacturing capabilities, and supported by quality‑management practices aligned with international standards, the company is rapidly asserting its strengths and demonstrating strong growth momentum.
The “1+3” strategy takes shape, fostering new drivers of development.
Looking ahead, while continuing to strengthen its core pharmaceutical business, Keyuan Pharmaceutical has established a “1+3” strategic framework: leveraging its existing portfolio of APIs, finished dosage forms, and intermediates as the foundational pillar, it is pursuing a tiered, phased expansion across three cutting-edge areas—glycemic control and weight management, anti‑aging biotechnology, and brain–computer interfaces. In doing so, the company is both solidifying its position as a leading pharmaceutical manufacturer and meticulously charting a second growth trajectory.
Embracing the world with openness and shaping the future through innovation, Keyuan Pharmaceutical is accelerating its growth—moving from deep cultivation of its core business to forward-looking strategic planning. By transforming the momentum of its core operations into a reliable driver of a second growth curve, the company is charting a new vision for high-quality development with an open mindset and a spirit of proactive advancement.
Previous
Latest News
Address: No. 26, Keyuan Street, Shanghe County, Jinan City, Shandong Province
Free Service Hotline